Life Sciences

OIG to focus on drug pricing fraud

Pharma Compliance Alert, October 8, 2008

The OIG will continue to scrutinize pharmaceutical drug pricing practices as part of the 2009 OIG Work Plan.
                     
The OIG plans to evaluate how quickly pharmaceutical companies submit their average manufacturer price (AMP) data to CMS. CMS uses AMP to calculate reimbursement rates, and pharmaceutical companies are required to submit AMP data every month under the Deficit Reduction Act. An OIG audit found AMP data missing for almost 14% of drugs.
 
The OIG will also evaluate how pharmaceutical companies calculate AMP.

Comments

0 comments on “OIG to focus on drug pricing fraud

 

Most Popular

Related Articles